Cargando…
Early skeletal muscle pathology and disease progress in the dy(3K)/dy(3K) mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency
Deficiency of laminin α2 chain leads to a severe form of congenital muscular dystrophy (LAMA2-CMD), and dystrophic symptoms progress rapidly in early childhood. Currently, there is no treatment for this detrimental disorder. Development of therapies is largely hindered by lack of understanding of me...
Autores principales: | Gawlik, Kinga I., Körner, Zandra, Oliveira, Bruno M., Durbeej, Madeleine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778073/ https://www.ncbi.nlm.nih.gov/pubmed/31586140 http://dx.doi.org/10.1038/s41598-019-50550-0 |
Ejemplares similares
-
Bortezomib Does Not Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Körner, Zandra, et al.
Publicado: (2016) -
Antioxidants Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Harandi, Vahid M., et al.
Publicado: (2020) -
Exploratory Profiling of Urine MicroRNAs in the
dy(2J)/dy(2J) Mouse Model
of LAMA2-CMD: Relation to Disease Progression
por: Moreira Soares Oliveira, Bernardo, et al.
Publicado: (2018) -
Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017) -
Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy
por: Gawlik, Kinga I., et al.
Publicado: (2017)